Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

Inclusion Criteria: * Histologically confirmed malignancy at original diagnosis or relapse (excluding intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of serum alpha-fetoprotein of beta-HCG) * Patients with recurrent or refractory solid tumors are eligible, including primary CNS tumors or patients with known CNS metastases * Current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life * Measurable or evaluable disease * No evidence of CNS hemorrhage on baseline MRI for patients with known CNS disease * Karnofsky performance status (PS) 50-100% (for patients \> 10 years of age) or Lansky PS 50-100% (for patients ≤ 10 years of age) * Neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 1 week prior to study entry * Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score * Patients with solid tumors without bone marrow involvement must meet the following criteria: * ANC ≥ 1,000/mm³ * Platelet count ≥ 100,000/mm³ (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) * Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions) * Negative protein dipstick OR urine protein \< 500 mg by 24-hour urine collection * Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine based on age/gender as follows: * 0.6 mg/dL for male and female patients 1 to \< 2 years of age * 0.8 mg/dL for male and female patients 2 to \< 6 years of age * 1.0 mg/dL for male and female patients 6 to \< 10 years of age * 1.2 mg/dL for male and female patients 10 to \< 13 years of age * 1.5 mg/dL (male) or 1.4 mg/dL (female) for patients 13 to \< 16 years of age * 1.7 mg/dL (male) or 1.4 mg/dL (female) for patients ≥ 16 years of age * Bilirubin ≤ 1.5 times upper limit of normal (U.N.) for age * SEPT (ALT) ≤ 110 μ/L (approx. 2.5 times U.N.) (for the purpose of this study, the U.N. for SEPT is 45 μ/L) * Serum albumin ≥ 2 g/dL * PT/aPTT \< 1.2 times U.N. * Patients must have a diastolic blood pressure ≤ the 95th percentile for age and gender and not be receiving treatment for hypertension * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No evidence of active graft-vs-host disease * No uncontrolled infection * No serious or nonhealing wound, ulcer, or bone fracture * No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to day 1 of study treatment * No clinically significant cardiovascular disease within the past 6 months, including any of the following: * History of cerebrovascular accident * New York Heart Association class III-IV congestive heart failure * Serious cardiac arrhythmia requiring medication * Unstable angina pectoris * Pulmonary embolism * Deep vein thrombosis * Other thromboembolic events * No evidence of a current bleeding diathesis or coagulopathy * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in the study * No significant traumatic injury within 4 weeks prior to day 1 of study treatment * Must be able to comply with the safety monitoring requirements of the study in the opinion of the investigator * Recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy * No prior aflibercept * At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea) * At least 6 weeks since prior monoclonal antibodies * At least 2 weeks since prior local palliative radiotherapy (small port) * At least 6 weeks since other prior substantial bone marrow radiotherapy * At least 2 months since prior stem cell transplantation or rescue * At least 3 months since prior total-body irradiation, craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis * At least 4 weeks since prior major surgical procedure, laparoscopic procedure, or open biopsy and no anticipation of need for major surgical procedures during the course of the study * At least 48 hours since prior fine needle aspirate, central line placement, or subcutaneous port placement * At least 1 week since prior core biopsy * At least 1 week since prior and no concurrent hematopoietic growth factors * At least 1 week since prior and no concurrent biologic agents * At least 1 week since prior and no concurrent dexamethasone * No concurrent antihypertensive medications for blood pressure control * No concurrent anti-thrombotic or anti-platelet agents (e.g., warfarin \[Coumadin ®\],heparin, low molecular weight heparin, aspirin, and/or ibuprofen, or other NSAIDs) * No concurrent medications known to inhibit platelet function or known to selectively inhibit cyclooxygenase-2 activity (e.g., all antipyretic and anti-inflammatory medications except acetaminophen) * No other concurrent anticancer therapy, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy * No other concurrent investigational drugs